Re:80% of current drug applications in China failed to meet ...
by brudgers on Sunday October 02, 2016 @01:03PM
(#12623240)
From the RFA story:
data gathered during clinical trials were incomplete, failed to meet analysis requirements or were untraceable, the paper cited a source in the agency as saying.
Outside of China, clinical data is often not shared, suppressed when it does not support the claims, and p-value hacking is used to justify 'off-label' use. This is not usually spun as fabricated, and in commercial drug development my intuition is that 80% of proposed drugs having at least one of these features would be a plausible hypothesis
data gathered during clinical trials were incomplete, failed to meet analysis requirements or were untraceable, the paper cited a source in the agency as saying.
Outside of China, clinical data is often not shared, suppressed when it does not support the claims, and p-value hacking is used to justify 'off-label' use. This is not usually spun as fabricated, and in commercial drug development my intuition is that 80% of proposed drugs having at least one of these features would be a plausible hypothesis